CLINICAL-STUDIES ON CELL-MEDIATED-IMMUNITY IN PATIENTS WITH URINARY-BLADDER CARCINOMA - BLASTOGENIC RESPONSE, INTERLEUKIN-2 PRODUCTION AND INTERFERON-GAMMA PRODUCTION OF LYMPHOCYTES

被引：22

作者：

IKEMOTO, S

KISHIMOTO, T

WADA, S

NISHIO, S

MAEKAWA, M

机构：

[1] Department of Urology, Osaka City University Medical School, Osaka

来源：

BRITISH JOURNAL OF UROLOGY | 1990年 / 65卷 / 04期

关键词：

D O I：

10.1111/j.1464-410X.1990.tb14751.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Summary— Patients with advanced malignant neoplasms have a variety of abnormal lymphocyte functions. We examined the PHA blastogenic response, interleukin‐2 (IL‐2) production and interferon‐y (IFN‐y) production of lymphocytes in 39 bladder cancer patients and 20 control subjects. Correlation between these parameters was also studied. IL‐2 production was measured by 3H‐thymidine‐labelled CTLL‐2 assay, and IFN‐γ production was measured by immunoradiometric assay using 2 mouse monoclonal antibodies. As a result, in high stage bladder cancer patients, the PHA blastogenic response, IL‐2 production and IFN‐γ production were impaired. However, these parameters were not significantly different between low stage bladder cancer patients and control subjects. There was a significant correlation between the PHA blastogenic response and IL‐2 production but no significant correlation between the PHA blastogenic response and IFN‐γ production. © 1990 British Journal of Urology

引用

页码：333 / 338

页数：6

共 32 条

[21]

NISHIO S, 1979, J UROLOGY, V116, P336

[22]

RASSIGAPIDOT AL, 1974, CANCER RES, V34, P2995

[23] HUMAN AUTOLOGOUS ROSETTES .4. THEIR RELATION WITH INTERLEUKIN-2 ACTIVITY PRODUCTION AND NATURAL-KILLER CELLS IN CANCER-PATIENTS [J].

REY, A ;

KLEIN, B ;

RUCHETON, M ;

CARAUX, J ;

ZAGURY, D ;

THIERRY, C ;

SERROU, B .

CELLULAR IMMUNOLOGY, 1984, 86 (01) :155-164

[24] OBSERVATIONS ON THE SYSTEMIC ADMINISTRATION OF AUTOLOGOUS LYMPHOKINE-ACTIVATED KILLER CELLS AND RECOMBINANT INTERLEUKIN-2 TO PATIENTS WITH METASTATIC CANCER [J].

ROSENBERG, SA ;

LOTZE, MT ;

MUUL, LM ;

LEITMAN, S ;

CHANG, AE ;

ETTINGHAUSEN, SE ;

MATORY, YL ;

SKIBBER, JM ;

SHILONI, E ;

VETTO, JT ;

SEIPP, CA ;

SIMPSON, C ;

REICHERT, CM .

NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (23) :1485-1492

[25]

SUZUKI R, 1983, J IMMUNOL, V130, P981

[26]

TAKAKU F, 1987, CANCER, V60, P929

[27]

TRICHIERI G, 1979, J EXP MED, V147, P1314

[28]

VONWUSSOW P, 1981, J IMMUNOL, V127, P1197

[29]

WADA S, 1985, J NATL CANCER I, V74, P659

[30]

WANEBO HJ, 1986, CANCER, V57, P656, DOI 10.1002/1097-0142(19860201)57:3<656::AID-CNCR2820570343>3.0.CO

← 1 2 3 4 →